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Background: Autism is a neurodevelopmental disorder of unknown etiopathogenesis associated with structural
and functional abnormalities of neurons and increased formation of reactive oxygen species. Our previous study
revealed enhanced accumulation of amino-terminally truncated amyloid-β (Aβ) in brain neurons and glia in
children and adults with autism. Verification of the hypothesis that intraneuronal Aβ may cause oxidative stress
was the aim of this study.
Results: The relationships between neuronal Aβ and oxidative stress markers—4-hydroxy-2-nonenal (HNE) and
malondialdehyde (MDA)—were examined in the frontal cortex from individuals aged 7–32 years with idiopathic
autism or with chromosome 15q11.2-q13 duplications (dup(15)) with autism, and age-matched controls.
Quantification of confocal microscopy images revealed significantly higher levels of neuronal N-truncated Aβ and
HNE and MDA in idiopathic autism and dup(15)/autism than in controls. Lipid peroxidation products were detected
in all mitochondria and lipofuscin deposits, in numerous autophagic vacuoles and lysosomes, and in less than 5%
of synapses. Neuronal Aβ was co-localized with HNE and MDA, and increased Aβ levels correlated with higher
levels of HNE and MDA.
Conclusions: The results suggest a self-enhancing pathological process in autism that is initiated by intraneuronal
deposition of N-truncated Aβ in childhood. The cascade of events includes altered APP metabolism and abnormal
intracellular accumulation of N-terminally truncated Aβ which is a source of reactive oxygen species, which in turn
increase the formation of lipid peroxidation products. The latter enhance Aβ deposition and sustain the cascade of
changes contributing to metabolic and functional impairments of neurons in autism of an unknown etiology and
caused by chromosome 15q11.2-q13 duplication.
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Autism is a complex neurodevelopmental disorder charac-
terized by impaired reciprocal social interactions, impaired
verbal and nonverbal communication, and stereotyped
patterns of repetitive behavior, with clinical symptoms de-
veloping in early childhood [1]. The cause of autism is un-
known, but a combination of genetic, epigenetic, and
environmental factors has been proposed to play a major
role in the etiology of autism. Certain genetic disorders* Correspondence: Janusz.Frackowiak@opwdd.ny.gov
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distribution, and reproduction in any mediumare associated with a particularly high incidence of autism,
e.g., it is as high as 69% among individuals who have a du-
plication of chromosome 15q11.2-q13 of maternal origin
[dup(15)] [2,3].
Altered metabolism of amyloid precursor protein (APP)
in autism is indicated by higher plasma levels of secreted
APP—two or more times—in children with severe autism
and aggression than in children without autism, and by
lower levels of amyloid-beta (Aβ) 40 than in controls [4,5].
Hence, an increased processing of APP by alpha-
secretases has been proposed to contribute to autism
[5,6]. Our recent postmortem studies demonstrated intra-
cellular deposits of Aβ truncated on the amino-terminaltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Frackowiak et al. Acta Neuropathologica Communications 2013, 1:61 Page 2 of 15
http://www.actaneurocomms.org/content/1/1/61side—the Aβ17-40/42—in neurons and glia in the brain
cortex, cerebellum and in subcortical nuclei. The percent-
age of amyloid-positive neurons as well as intraneuronal
Aβ load were significantly higher in individuals diagnosed
with idiopathic autism and in subjects diagnosed with dup
(15) and autism spectrum disorder (ASD) than in controls
[7]. The pathological consequences of intracellular accu-
mulation of N-truncated Aβ by neurons and glia are not
known. However, accumulation of full-length Aβ 1-42 and
Aβ 1-40 in Alzheimer’s disease and Down syndrome is as-
sociated with production of reactive oxygen species and
contributes to oxidative stress [8-10].
Increased formation of reactive oxygen species has
been implicated in the pathophysiology of autism, and
markers of oxidative stress have been detected in autism,
even at an early age. Peripheral blood in children with
autism contains elevated levels of malondialdehyde
(MDA), an indicator of lipid peroxidation [11], and in-
creased levels of thiobarbituric acid–reactive substances
(TBARS) [12]. Increased oxidative stress in children with
autism was also suggested by increased nitric oxide
(NO) levels in red blood cells [13] and higher urinary ex-
cretion of TBARS, lipid hydroperoxides, 4-hydroxy-2-
nonenal (HNE), and protein carbonyls along with low
levels of urine antioxidants [14]. Severity of autism
appears to be correlated with urinary excretion of 8-
isoprostane-F2 alpha [15]. A link of oxidative stress in
autism to malfunction of anti-oxidative mechanisms is
indicated by reduced serum levels of ceruloplasmin and
transferrin—the major proteins with anti-oxidative prop-
erties [11], as well as significantly lower ratio of reduced/
oxidized glutathione in the plasma, decreased methionine
cycle turnover [16,17], increased plasma activities of gluta-
thione peroxidase [13], xanthine oxidase and superoxide
dismutase (SOD) [12], and decreased catalase activity [12].
Oxidative stress in the brain in autism is indicated by
oxidative DNA damage: increased levels of 3-nitrotyrosine
(3-NT) [18-20] and 8-oxo-deoxyguanosine [18]. The dis-
tribution of 3-NT indicates brain region–specific en-
hancement of oxidative stress, particularly in cerebellum
and cortical areas involved in speech processing, sensory
and motor coordination, emotional and social behaviors,
and memory [20]. Other biomarkers of oxidative stress—
reduced glutathione (GSH) levels, and decreased ratio of
GSH to oxidized glutathione in cerebellum and temporal
cortex—indicate a role of deficient glutathione antioxidant
defense in certain brain regions in the development of oxi-
dative stress in autism [18,21]. The pathomechanisms of
oxidative stress in autism have not been determined; how-
ever, it can be attributed, in part, to activation of the
immune system, which has been confirmed in the brain
[22] and in the peripheral blood [23]. Significantly higher
levels of 3-chlorotyrosine—a biomarker of a chronic in-
flammatory response—in cerebellum and temporal cortexmay link oxidative stress in the brain in autism with a
chronic inflammatory response, whereas a decreased
aconitase activity in the cerebellum in autism indicates in-
creased mitochondrial superoxide production [18].
The aim of this project was to test the hypothesis that
intracellular deposits of N-truncated Aβ are not bio-
logically neutral, but may be a source of reactive oxygen
species in brain cortex neurons in subjects with idio-
pathic autism and in subjects with dup(15) with autism.
Methods
Brain tissue
Samples of autopsy brain frontal cortex, formalin-fixed
and frozen, were obtained from the Brain Bank and
Tissue Bank for Developmental Disabilities and Aging,
of the New York State Institute for Basic Research
in Developmental Disabilities Staten Island, NY, the
Harvard Brain Tissue Resource Center, Belmont, MA,
and the NICHD Brain and Tissue Bank for Developmen-
tal Disorders, University of Maryland School of Medi-
cine, Baltimore, MD (Tables 1 and 2). Selection of this
brain region was based on neuropathological changes
detected in autism [24]. Idiopathic autism was confirmed
by Autism Diagnostic Interview–Revised (ADI-R) score.
Duplication of 15q11.2-q13 was confirmed by genotyp-
ing with 19–33 short tandem repeat polymorphisms
from chromosome 15, custom and/or array comparative
genomic hybridization (array CGH), Southern blot ana-
lysis of dosage with 5–12 probes, and fluorescent in situ
hybridization performed using antemortem peripheral
blood samples and lymphoblast cell lines [2,3].
Immunofluorescence and confocal microscopy
Free-floating 50-μm sections of formalin-fixed and poly-
ethylene glycol–embedded frontal cortex containing
Brodmann cortical areas 9 and 46 were used for detec-
tion of Aβ, lipid peroxidation products, and markers of
cell organelles by immunofluorescence and confocal mi-
croscopy. The antibodies used are listed in Table 3.
Secondary antibodies were affinity-purified donkey anti-
sera labeled with Alexa 488 or 555 specific for the re-
spective species (Invitrogen/Molecular Probes, Grand
Island, NY, USA). Nuclei were counterstained with TO-
PRO-3-iodide (TOPRO-3i) (Invitrogen/Molecular Probes).
Images were collected using a Nikon C1 confocal micro-
scope system and with EZC1 image analysis software. The
images were used for further immunofluorescence quanti-
fication, basing on previous studies which have shown that
measurements of immunofluorescence staining allow rela-
tive protein quantification in tissue sections when properly
standardized methods are used [25]. The guidelines for
proper image acquisition and controlling factors that
affect the accuracy and precision of quantitative fluores-
cence microscopy were applied [26]. To ensure unbiased
Table 1 Formalin-fixed brains tested
Group Brain bank number Sex Age years Cause of death PMI
dup(15) B-7359 M 9 Cardiac arrest 13.6
dup(15) B-7741 M 10 SUDEP 17.7
dup(15) B-7014 M 11 Seizure-related 10.5
dup(15) B-6973 F 15 SUDEP 24
dup(15) B-7619 F 15 Aspiration pneumonia -
dup(15) B-7041 M 20 Cardiac arrest, resusc./ventilation 28
dup(15) B-7436 M 24 Seizure-related 36
Autism HSB4640 M 8 Asthma attack 13.8
Autism B-6349 M 9 Cardiopulmonary arrest 3.8
Autism CAL105 M 11 drowning -
Autism CNL93-01 M 23 Seizure related 14
Autism B-6994 M 28 Seizure-related 43
Autism NP06-54 M 32 Brain tumor -
Control UMB1706 F 8 Rejection of cardiac transplant 20
Control UMB1670 M 14 Asphyxia (hanging) 5
Control UMB4722 M 14 Multiple traumatic injuries 16
Control BTB3960 F 25 Not known 26
Control CNL291-00 M 32 Heart failure 14
Control CNL212-98 F 33 bronchopneumonia 16
NOTE: postmortem interval (PMI); Sudden unexpected and unexplained death of subject with known epilepsy (SUDEP).
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tensity, sections were coded and microscopic fields in the
3rd and 5th cortical layers were randomly selected in the
blue channel in which only cell nuclei and cytoplasm were
visible, and large pyramidal neurons were identified by their
morphology. For measurements, confocal image layers
containing cytoplasm and nucleus of pyramidal neurons
were selected. Images in three channels were collected at
the amplifications at which the background staining was
minimal, and the settings of channel amplification were the
same for all groups tested. Specificity of immunostainings
was confirmed as previously described [27-29]. The back-
ground autofluorescence for pyramidal neurons and neuro-
pil was measured in unstained sections and in sections
stained with omission of primary antibodies. Specific
immuofluorescence was calculated after subtracting auto-
fluorescence and nonspecific background fluorescence. The
levels of immunofluorescence intensities for Aβ, HNE, and
MDA were measured using Image J software (NIH), and
specific immunostainings were calculated per 1,000 pixels
of cell contour or random samples of surrounding neuropil
of the pixel size comparable to neurons. For each brain and
each immunostaining an average of 38 cells were measured.
Blood vessels were excluded from measurements.
Immunoblotting
Samples of frozen frontal cortex were homogenized in
glass-teflon homogenizer in 10 mM TRIS buffer, pH 7.5,containing 0.15 M NaCl, 0.65% NP-40, and protease
inhibitor cocktail (Roche Diagn. GmbH, Mannheim,
Germany), and blood vessels and leptomeninges were re-
moved by passing through 75 μm nylon mesh. Protein
contents were measured using the BCA protein assay
(Pierce, Rockford, IL). Samples of brain lysates were
centrifuged at 10,000 g for 10 min, and supernatants and
pellets were collected. Samples containing 20 μg of pro-
tein lysate as well as supernatants and pellets obtained
from 20-μg samples of full lysate were subjected to SDS-
PAGE (8% tris/tricine gels). Full lysates (10 μg protein
samples) were used for slot blotting. Proteins modified
by MDA and HNE were detected with the antibodies
listed in Table 3. The levels of actin were used as sample
load controls. Densitometrical measurements of bands
on membranes were performed with SigmaGel software
(Jandel Sci., San Raphael, CA, USA).Statistical analysis
For all data groups the degrees of asymmetry of the data
distribution around mean values have been calculated.
Because the data did not have normal distribution (mea-
sured as skewness of the distribution) natural logarithms
of values were used for the Student’s t-test analysis. To
test specific hypotheses, pairwise comparisons were cal-
culated using Student’s t-test adjusted for the non-
homogeneity of variance between two groups.
Table 2 Frozen brains tested
Group Brain bank number Sex Age years Cause of death PMI
dup(15) B-7359 M 9 cardiac arrest in seizures 13.6
dup(15) B-7014 M 11 seizure-related 10.5
dup(15) B-7041 M 20 Cardiac arrest, resusc./ventilation 28
dup(15) B-6856 F 26 asphyxia, seizure suspected 28.6
Autism UMB-5144 M 7 complications of tumor 3
Autism UMB-4849 M 7 drowning 20
Autism CNL-1480 M 8 asthma 13.8
Autism UMB-4721 M 8 drowning 16
Autism B-5342 F 11 drowning during seizures 13
Autism UMB-4899 M 14 drowning 9
Autism UMB-5278 F 16 drowning in seizure disorder 13
Autism UMB-5176 M 22 SUDEP 18
Autism B-6640 F 29 seizure disorder 18
Control UMB-4898 M 7 drowning 12
Control UMB-4337 M 8 neck injury 16
Control UMB-5391 M 8 drowning 12
Control UMB-5161 F 10 accident-hanging 22
Control UMB-5334 M 12 suicide-hanging 15
Control CNL-1398 M 13 asphyxia-hanging 5
Control UMB-4722 M 14 multiple injuries 16
Control UMB-5163 M 15 drowning 12
Control UMB-5168 F 16 cardiac arrhythmia 11
Control B-5251 M 19 pneumonia 18.6
Control UMB-4590 M 20 cardiac arrest 19
Control B-5718 M 22 N/A 21.5
Control UMB-818 M 27 accident - multiple injuries 10
Control CNL-247 M 31 N/A 3
Control CNL-1169 M 32 congestive heart failure 14
NOTE: postmortem interval (PMI); not assigned (N/A); Sudden unexpected and unexplained death of subject with known epilepsy (SUDEP).
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Immunohistochemical reactions for Aβ
Aβ immunoreactivity was detected in neurons, glia, and
in neuropil by immunofluorescence and confocal mi-
croscopy in all the control, idiopathic autism, and dup
(15)/autism brain tissue samples. The intraneuronal Aβ
deposits immunoreacted with two antibodies against dis-
tinct Aβ epitopes: mAb 4G8, specific for the 17-21
aminoacids of the Aβ sequence (Figure 1a) and R226,
specific for aa 36-42 of Aβ (not shown) but revealed al-
most no reaction with mAb 6E10, specific for aa 4-13 of
Aβ (Figure 1a), indicating that the deposits contained N-
terminally truncated Aβ, consistent with Aβ 17-40/42 or
Aβ 11-40/42 (the products of secretase-α and –γ, or
secretase-β and –γ, respectively), or other Aβ species.
The N-truncated Aβ was detected in up to 60% of large
pyramidal neurons in the frontal cortex in the dup(15)/autistic subjects, and in 30– 45% of neurons in idio-
pathic autism. Control brains contained a weaker immu-
noreactivity for N-truncated Aβ, which was detected in
15–35% of neurons. The intracellular Aβ-immunoreactive
granules were of diameter 0.3–2.5 μm, and their numbers
in individual large pyramidal neurons in layers 3 and 5
varied greatly in each case in every group tested, from no
reaction or a few granules, to multiple granules filling the
pericaryon (Figure 1a). The morphology of nuclei in cells
without and with Aβ deposits was similar, and chromatin
did not show changes typical for apoptosis. Between 10%
and 50% of intraneuronal deposits of Aβ were co-localized
with autofluorescent material consistent with lipofuscin
granules (Figure 1a).
To quantify the intensities of immunostaining, the spe-
cific immunofluorescence, i.e., immunofluorescence after
subtraction of nonspecific background fluorescence and
Table 3 Antibodies used for immunohistochemistry and for immunoblotting
Name Epitope or target Dilution Host/type Source
6E10 4-13 aa Aβ 1:2,000 M-monocl Signet Laboratories (antibody developed at IBRDD [30,31])
4G8 17-21 aa Aβ 1:2,000 M-monocl IBRDD [30,32]
R226 36-42 1:40 R-polycl. IBRDD [33]
Anti-MDA malondialdehyde 1:500 R-polycl Alpha Diagnostic Int., San Antonio, TX
G-polycl
Anti-HNE 4-hydroxy-2-nonenal 1:500 R-polycl Alpha Diagnostic Int., San Antonio, TX
COX IV Mitochondria 1:100 R-monocl Cell Signaling Technology
LAMP 1 Lysosomes 1:400 R-polycl Abgent
actin actin 1:4000 M-monocl Pierce/Thermo Sci., Rockford, IL
LC3B Autophagic vacuoles 1:100 R-monocl Cell Signaling Technology Danvers, MA
8C4 Tripeptidyl peptidase I 1:30 M-monocl IBRDD [34]
GFAP Astrocytes 1:400 R-polycl Sigma, St. Louis, MO
SP15 synaptophysin 1:100 M-monocl Calbiochem-EMD Biosciences, Inc., La Jolla, CA
synaptophysin synaptophysin 1:200 G-polycl GeneTex, Irvine, CA
Antibodies were monoclonal or polyclonal: Mouse (M); Rabbit (R) or Goat (G).
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The average intensities of specific reactions for Aβ mea-
sured in pyramidal neurons in the confocal image layer
containing cytoplasm and nucleus were significantly
higher in dup(15)/autism and in idiopathic autism than in
controls (p < 0.001). The reactions in dup(15)/autism were
significantly more intense than in idiopathic autism
(p < 0.01) (Figure 1b, Aβ bars). The intensities of the
immunoreactions for Aβ in the neuropil did not differ
between the groups studied.
Lipid peroxidation products
Immunoreactivities for HNE and for MDA were detected
in all layers of the frontal cortex in all the brains examined
that were diagnosed with idiopathic autism or dup(15)/
autism and in controls. The immunoreactions for HNE
and for MDA were detected in granules with diameter
0.25–3.5 μm, located in the cytoplasm of neurons and glia,
in the neuropil, and in blood vessel walls. To characterize
the subcellular localization of lipid peroxidation products
in large pyramidal neurons in layers 3 and 5, their pres-
ence in mitochondria, autophagic vacuoles, lysosomes,
and lipofuscin was verified by confocal microscopy. Mito-
chondria were visualized with an antibody against cyto-
chrome c oxidase, COX IV. The intraneuronal granules
that were most intensely immunoreactive for HNE or
MDA were frequently identified as COX IV–positive
mitochondria in dup(15)/autism (Figure 2) and in idio-
pathic autism (not shown). However, the majority of neu-
ronal granular immunoreaction for lipid peroxidation
products was not associated with mitochondria. Mito-
chondria in control brains contained lipid peroxidation
products but the immunoreactions were much weaker
than in dup(15) and autism (Figure 2).Autophagic vacuoles were detected with an antibody
against the LC3B marker. Between 30% and 60% of
LC3B-positive granules were immunoreactive for MDA
(Figure 2) and HNE (not shown) but these organelles
contained no more than 5–10% of all granules immuno-
reactive for lipid peroxidation products in neurons.
Lysosomes and late endosomes, detected by the pres-
ence of Lamp-1 glycoprotein, contained granules react-
ive for HNE and MDA, but only about 30% of
lysosomes/enodomes were the site of prominent accu-
mulation of lipid peroxidation products in autism, dup
(15)/autism and controls (Figure 2). Among the lyso-
somes identified by the presence of tripeptidyl peptidase
I—a lysosomal peptidase with a broad substrate specifi-
city—up to 50% contained a significant or strong reac-
tion for lipid peroxidation products (Figure 3, TTP).
Between 30% and 50% of pyramidal neurons in autism
and in dup(15)/autism contained intracellular granules
that revealed a wide-spectrum autofluorescence detected
in the red-orange, green, and deep red channels—con-
sistent with the properties of lipofuscin. The number of
autofluorescent lipofuscin granules varied from a single
profile to over 20 in a single cell image. They all were
immunoreactive for HNE and MDA; however, only a mi-
nority of all neuronal immunoreactivities for both lipid
peroxidation products was associated with autofluorescent
lipofuscin (Figure 3).
Nuclear immunoreactions for HNE and MDA in
large pyramidal neurons showed a significant variabi-
lity between the cases and between individual neurons
in each brain. Each brain that was tested contained
large pyramidal neurons in the frontal cortex with in-
tense as well as with scanty immunoreactions
(Figures 2, 3, 4).
Figure 1 N-terminally truncated Aβ in pyramidal neurons in frontal cortex in confocal microscopy and semi-quantification of
N-truncated Aβ, HNE and MDA in neurons and in neuropil. (a) Large pyramidal neurons in frontal cortex in layers 3 and 5 in a 10-year-old
individual with dup(15)/autism contain granules immunoreactive with mAb 4G8, but not with 6E10, consistent with N-terminally truncated Aβ.
Between 20% and 40% of intracellular granular Aβ in this brain are co-localized with autofluorescent granules of lipofuscin. Bars 10 μm. (b)
Intensities of the Aβ, MDA and HNE immunoreactivities in individual neurons in the frontal cortex for all brains listed in Table 1 are significantly
larger in the dup(15)/autism cases and in the idiopathic autism than in controls. The bars show average + SD. Statistical significance: * p < 0.05,
*** p < 0.001.
Frackowiak et al. Acta Neuropathologica Communications 2013, 1:61 Page 6 of 15
http://www.actaneurocomms.org/content/1/1/61Granular reactions for HNE and MDA were also lo-
cated in the neuropil. Up to 15% of these HNE- and
MDA-reactive profiles were co-localized with synapses,
as indicated by double staining for synaptophysin
(Figure 4). The percentage of synapses that contained
granules immunoreactive for MDA or HNE was 1.5–5%
in dup(15)/autism and idiopathic autism and control.
Measurements of intensities of specific immunoreac-
tivity for HNE and MDA detected in individual pyra-
midal neurons in the confocal image layers containing
cytoplasm and nucleus revealed significantly higher averagelevels in dup(15)/autism and in autism than in controls
(p < 0.001). The signals in the dup(15)/autism samples
were significantly more intense than in idiopathic au-
tism (p < 0.01). The immunoreactions for lipid peroxi-
dation products in the neuropil were similar in the
groups studied (Figure 1b: HNE and MDA bars).
Proteins modified with HNE and MDA revealed by im-
munoblotting were of the molecular sizes 50–180 kD in
samples from autistic and control subjects. More than
85% of the modified proteins were soluble in low concen-
trations of detergent—0.65% Nonidet NP-40 (Figure 5).
Figure 2 MDA immunoreactivity in large pyramidal neurons in layers 3 or 5 of frontal cortex in 10-year-old individual with dup(15)/
autism [dup(15)] and in 8-year-old control subject (contr) brains. Mitochondria, visualized by immunostaining for cytochrome c oxidase COX
IV, were the site of weak reactivity for MDA in control but a strong reactivity in dup(15)/autism brain. Most autophagic vacuoles (detected with
antibody LC3B) and lysosomes/late endosomes (detected by the presence of Lamp-1 glycoprotein) did not contain a significant fraction of MDA.
Bars 10 μm.
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size and intensity of the HNE- and MDA-modified protein
bands detected in lysates, 10,000 g pellets or supernatants
in the control and autism groups, and none of these
HNE- and MDA-modified proteins was specific for au-
tism. The levels of total MDA- and HNE-modified pro-
teins detected in slot blots were similar in dup(15)/
autism, idiopathic autism and in controls (Figure 5).
The relationship between localization and levels of Aβ
and lipid peroxidation products
Double immunostaining and confocal microscopy re-
vealed that the intracellular Aβ was almost entirely co-
localized with HNE and MDA in all groups, with a notable
exception of the smallest granules, typically of diameter
up to 0.3 μm but infrequently reaching the diameter of1 μm, which did not reveal reactions for lipid peroxidation
products (Figure 6).
The specific immunofluorescence for Aβ and for
HNE and MDA was measured in individual neurons
and in neuropil. Neurons with cytoplasmic Aβ gran-
ules contained granules reactive for HNE and MDA
that were more numerous and more intensely stained
as compared to cells that were Aβ-negative as well as
to the surrounding neuropil. This relationship was
observed in all groups studied. In control brains, the
granular reactions for HNE and MDA were in the
majority of neurons with similar intensities and distri-
bution as in the surrounding neuropil, and stronger
immunoreactions for HNE and for MDA were
detected only in neurons immunoreactive for Aβ
(Figure 7).
Figure 3 Large pyramidal neurons in layer 5 of frontal cortex in 10-year-old individual with dup(15)/autism. Lysosomes identified by the
presence of tripeptidyl peptidase I (TPP), characteristic for activated cells (using mAb 8C4), were detected in cells with more intense
immunoreactivity for HNE. Up to 50% of these lysosomes immunoreacted strongly for HNE. Lipofuscin, detected as autofluorescent granules in
green channel, contained strong reactivities for HNE and MDA, but most lipid peroxidation products were not located in lipofuscin. Bars 10 μm.
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autism were stronger than in control brains (Figure 1b,
cells: HNE, MDA). The intensities of the HNE and MDA
immunoreactions measured in individual cells were posi-
tively correlated with the amounts of Aβ immunoreacti-
vity: the Pearson correlation coefficient values were r = 0.64Figure 4 HNE and MDA in 23-year-old individual with idiopathic autis
synaptic terminals (detected by the presence of synaptophysin) contained(p < 0.001) and r = 0.74 (p < 0.001), respectively (Figure 8).
In dup(15)/autism the neuronal reactions for MDA were
stronger than in control brains and in idiopathic autism
(Figure 1b, cells: HNE, MDA). The intensities of the
immunoreactions for MDA measured in individual cells
were correlated with the amounts of Aβ immunoreactivitym and in 10-year-old individual with dup(15)/autism. Up to 5% of
lipid peroxidation products. Bars 10 μm.
Figure 5 HNE- and MDA-modified proteins in brain lysates. (a) HNE- and MDA-modified proteins detected by immunoblotting in frontal
cortex lysates of autism and control brains (lanes L). More than 85% of the modified proteins were detected in supernatant (S) after
centrifugation at 10,000 g for 10 min, but not in the pellet (P). (b) The levels of total MDA- and HNE-modified proteins in lysates normalized to
actin levels, as detected by slot blotting in all brains listed in Table 2, were similar in dup(15)/autism, idiopathic autism and in controls.
Frackowiak et al. Acta Neuropathologica Communications 2013, 1:61 Page 9 of 15
http://www.actaneurocomms.org/content/1/1/61(r = 0.76, p < 0.001) (Figure 9). In one 11- year-old
individual with dup(15)/autism, large pyramidal
neurons in layers 3 and 5 with intracellular Aβ con-
tained a strong immunoreaction for MDA close to
the neuronal plasma membrane (Figure 9b). DoubleFigure 6 Co-localization of Aβ and HNE and MDA. Intracellular product
diameter 0.25–3.5 μm. Aβ is co-localized with intracellular HNE products w
diameter less than 0.3 μm, but infrequently also larger—up to 1 μm, as shoimmunostaining for Aβ and HNE in dup(15)/autism
revealed stronger neuronal HNE reactions than in
control brains and in idiopathic autism (Figure 1b,
cells: HNE). Two populations of neurons of similar
numerical densities were revealed among cells withs of lipid peroxidation—HNE and MDA—appear as granules with
ith the notable exception of the smallest Aβ granules, typically with
wn in dup(15)/autism and control brains. Bars 10 μm.
Figure 7 Brains of control individuals, 8 years old and 25 years old contain intracellular granular immunoreactions HNE and MDA, the
intensities of which are correlated with the amounts of accumulated Aβ, as shown in the confocal images. Bars 10 μm. The graphs show
the relationship between Aβ and HNE or MDA for neurons in all control cases listed in Table 1.
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HNE ratios, equal to 0.147 and 0.786 for the popula-
tion with stronger and less intense immunoreactions
for HNE, respectively (Figure 9). The intensity of
neuronal Aβ immunoreaction was correlated with that
for HNE; the correlation coefficient in the populations
with higher and lower Aβ/HNE ratio was 0.77 (p < 0.001)
and 0.79 (p < 0.001), respectively.
Discussion
Oxidative stress has been detected in the brain and in
peripheral organs of autistic subjects [11-13,18-21]. Our
data link intraneuronal accumulation of N-terminally
truncated Aβ in dup(15)/autism and in idiopathic autism
to elevated intracellular levels of lipid peroxidation prod-
ucts, the accepted markers of oxidative stress. Analysis of
the relationship between deposits of Aβ of various sizes
and oxidatively modified lipids in three-color immuno-
fluorescence revealed almost complete co-localization of
intracellular Aβ with lipid peroxidation products in aut-
ism, dup(15)/autism and control brains. However, the ab-
sence of HNE and MDA in the majority of the smallest
Aβ immunoreactive granules, apparently representing the
earliest steps of Aβ accumulation, suggests that cellularaccumulation of Aβ precedes formation of lipid peroxida-
tion products. Hence, Aβ deposits are most likely the
source of oxidative stress, rather than oxidative stress
being the trigger for Aβ accumulation.
Our present and previous [7] studies revealed higher
levels of accumulation of N-truncated Aβ in neurons in
individuals with idiopathic autism and with dup(15)/au-
tism, than in controls. Detection of Aβ and its N-terminal
truncation in both projects was based on immunohisto-
chemical detection with mAbs 4G8 (17–21 aa of the Aβ
sequence [30,32]) but not 6E10 (4–13 aa). Even though
these antibodies can recognize the epitopes in full-length
APP and in APP fragments [35], in human brains fixed in
formalin for at least several months, dehydrated in ethanol
and embedded in polyethylene glycol the mAbs 4G8 and
6E10 do not react with APP, but detect only Aβ [7,27,28].
Thus, the deposited Aβ species are most likely mainly
Aβ17-40/42 [36], Aβ11-40/42 [36,37], Aβ11(pE)-40/42
[38], and possibly also other.
To evaluate the amounts of Aβ and also lipid peroxi-
dation products we applied in this report measuremets
of fluorescence in digital images, instead of morpho-
logical evaluation of intensity of the immunoreaction.
This new approach—quantification of relative protein
Figure 8 Brains of individuals diagnosed with idiopathic autism, 23 and 24 years old. The HNE and MDA intracellular immunoreactions are
co-localized with Aβ, as shown in the confocal images, and their intensities are correlated with the amounts of accumulated Aβ. Bars 10 μm. The
graphs demonstrate the correlation between the intensities of the immunoreactions measured for Aβ and HNE and MDA in all autism cases
listed in Table 1.
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been recently shown to be a reliable method [39]. Using
known aliquots of cytochrome C embedded in gelatin
these authors revealed a high accordance of the amounts
of protein detected with primary and secondary anti-
bodies and fluorescence microscopy with the actual pro-
tein levels present.
The presence of large deposits of N-truncated Aβ in-
side neurons suggests that the peptide is, at least in part,
aggregated. N-truncation of Aβ peptides is known to en-
hance their aggregation and formation of the β-sheet
structure [40]. The biological effects of accumulation of
N-truncated Aβ are not well characterized. The peptides
have neurotoxic properties—especially the Aβ 17-42 spe-
cies [40,41]—leading to apoptosis mediated mainly by
the caspase-8 and caspase-3 pathways [41]. However, we
did not observe apoptotic nuclei in neurons, possibly be-
cause of the young age of the subjects. Aggregated and
oligomerized full-length Aβ 1-40/42 is involved in the
formation of reactive oxygen species through binding
transitional metals copper and iron. N-terminal trunca-
tion of Aβ lowers the ability to form reactive oxygenspecies, because copper is bound to His6, His13 and
His14, in the N-terminal sequence of Aβ, whereas the
carbonyl of alanine-2 is an oxygen ligand [10]. However,
methionine-35 can also be oxidized to form a sulfuranyl
radical, which subsequently can cause lipid peroxidation
[8,9]. These data and the results presented in this study
suggest that enhanced accumulation of intracellular N-
truncated Aβ may result in increased production of re-
active oxygen species and increased formation of lipid
peroxidation products.
Our finding of higher levels of lipid peroxidation prod-
ucts in neurons in autism and dup(15)/autism than in
controls is in agreement with the reported significantly
increased levels of MDA in lysates of the cerebral cortex
and cerebellum of autistic subjects [42]. The localization
of lipid peroxidation products in almost all mitochon-
dria, in some autophagic vacuoles and lysosomes, and in
all lipofuscin granules most likely reflects the sites of for-
mation of lipid peroxidation products, their intracellular
trafficking, and storage of non-degradable components.
Mitochondria generate the superoxide anion radical
(O2*-), hydrogen peroxide (H2O2), and hydroxyl radical
Figure 9 Brains of individuals diagnosed with dup(15)/autism, 10 and 11 years old. Confocal microscopy revealed Aβ in more than 50% of
frontal cortex neurons in the dup(15) with autism. The immunoreactivity for HNE is granular and is located in neurons, glia and neuropil.
Intracellular deposits of Aβ are the sites of strong accumulation of MDA (a), but in one case of dup(15)/autism (b), large pyramidal neurons in
layers 3 and 5 in the cortex accumulating Aβ contain a particularly strong immunoreaction for MDA in the vicinity of plasma membrane. The
reactions for lipid peroxidation products are correlated with cellular immunoreactivity for Aβ. Bars 10 μm. Measurements of the intensities of
immunoreactions for Aβ and HNE in all dup(15) cases listed in Table 1 shown in the graph reveal two populations of neurons with distinct
intracellular Aβ/HNE ratios.
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[43]). The increased levels of lipid peroxidation products
in mitochondria in idiopathic autism and dup(15)/aut-
ism (Figure 2), as well as their co-localization with N-
truncated Aβ, may have very significant biological
consequences for the neuron. In mitochondria, MDA
has an inhibitory effect on mitochondrial complex I- and
complex II-linked respiration and significantly elevates
production of reactive oxygen species and protein car-
bonyls [44]. Thus, increased formation of HNE and
MDA in neurons with N-truncated Aβ deposits may en-
hance the formation of reactive oxygen species in mito-
chondria and may be the cause of, or enhance an existingmitochondrial dysfunction in autism and dup(15)/autism.
Impaired mitochondrial function has been detected in
children with autism, with increased rates of hydrogen
peroxide production [45], and reduced expression of nu-
merous genes of mitochondrial complex I, III, IV, and V
[46]. In autism the levels of HNE protein adducts are also
increased in erythrocyte membranes and in plasma; the
imbalance between pro- and anti-oxidative mechanisms
may be linked to higher levels of unbound iron [47].
The presence of lipid peroxidation products in lyso-
somes and in all lipofuscin granules in neurons reflects
the sites of processing of oxidatively modified molecules,
which are known to be partially degraded in lysosomes
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http://www.actaneurocomms.org/content/1/1/61and deposited in lipofuscin [48,49]. Detection of lipofuscin
in brain neurons in children with autism, even younger
than 10 years of age, is in agreement with the reported pre-
viously increased frequency of cells containing lipofuscin—
particularly in Brodmann areas 22 and 39—in autism [50].
We have not found significantly increased levels of
total HNE- and MDA-modified proteins in whole brain
lysates, possibly because the Aβ-accumulating neurons
constitute only a minor portion of the brain cortex, or
because significant fractions of HNE and MDA detected
by immunofluorescence were not protein-bound. How-
ever, lipid peroxidation products are known to modify
proteins. The binding is aminoacid–specific: for HNE, it
is histidine (particularly when flanked by basic amino
acid residues), and less frequently Cys, and Lys. Proteins
particularly susceptible to modifications by HNE include
enzymes involved in glycolysis and ribosomal proteins
[51]. Covalent binding of HNE to enzymes frequently
causes their quick inactivation e.g., glyceraldehyde-3-
phosphate dehydrogenase [52] and ion-transporting
ATPases [53,54].
Detection of HNE and MDA in the nuclei of numer-
ous neurons points out to yet another possible biological
effect of lipid peroxidation products—their influence on
transcription. MDA reacts with DNA forming guanine
derivatives, which in the transcribed DNA strand of
expressed genes strongly inhibit RNA polymerase II
[55]. MDA can also affect transcription through modi-
fication of aldehyde dehydrogenase 2—which in the
nucleus plays an important role in transcription re-
pression through its interaction with histone
deacetylases—by inhibiting its nuclear translocation
and its repressive activity in general transcription
[56]. The great variability of nuclear reactions for HNE
and MDA (Figures 4, 6, 7, 8, 9) suggests that susceptibility
for this effect of lipid peroxidation products may vary
among cell subpopulations.
Cellular co-localization of lipid peroxidation products
and Aβ may have significant biological consequences.
HNE may covalently bind Aβ at multiple locations
through 1,4 conjugate addition and/or Schiff base for-
mation, which leads to covalent cross-linking of Aβ and
formation of Aβ protofibrils [57]. Furthermore, oxidative
stress can even trigger deposition Aβ, as shown for
cultured brain vascular smooth muscle cells [28,29]. Ac-
cumulation of HNE may also increase neuronal levels
and secretion of Aβ by up-regulating expression of
BACE-1—APP secretase-β—through activation of the
c-Jun N-terminal kinases and p38 [58]. Increased Aβ levels
and oxidative stress in neuronal progenitor cells may impair
neurogenensis in postnatal brain. Full-length Aβ—even the
less neurotoxic species 1-40—causes oxidative damage in
human neuronal progenitor cells and impairs prolifera-
tion, migration, and formation of processes [59].Analysis of the levels of Aβ and HNE in individual
neurons indicates the existence of two neuronal popula-
tions in the frontal cortex with a distinct relationship be-
tween accumulation of Aβ and HNE: in one, the ratio is
similar to that for Aβ and MDA; in the other, moderate
contents of Aβ were accompanied by a massive accumu-
lation of HNE. This significantly enhanced formation of
HNE in a subpopulation of neurons could be related to
some neuronal lineages and/or to a certain functional state
of neuron. Further studies are necessary to characterize
cells with these properties.
Conclusions
We propose that formation of deposits of N-truncated
Aβ, which become a source of reactive oxygen species
and lipid peroxidation products, causes neuronal dys-
function in autism. Accumulation of lipid peroxidation
products causes/increases dysfunction of mitochondria
and further increases Aβ accumulation leading to a self-
enhancing process. Thus, autism appears to be an Aβ-
associated disorder with enhanced non-amyloidogenic
processing of APP and abnormal cytoplasmic accumula-
tion and trafficking of N-terminally truncated Aβ, which
lead to enhanced oxidative stress and mitochondrial in-
jury, contributing to abnormal neuron development and
function.
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